Priority topics

Areas covered will include:

• Novel techniques to evaluate exertional breathlessness
• Evaluation of diaphragm dysfunction and treatment modalities
• Utilising the real-world digital data to enhance respiratory patient care
• What do pulmonary clinicians need to know about sports repeated breathing issues?
• Lung sounds analysis (early detection of exacerbations)
• Transitioning to the responsible AI in respiratory care: building trust, enhancing digital skills
• Pulmonary toxicity in newer oncology drugs particularly immune therapy

Areas covered will include:

• End-of-life care in acute and chronic mechanical ventilation
• Phenotyping of ARDS and individualised therapy
• Diagnostic and treatment of severe CAP and ARDS
• Mobilisation and rehab: from ICU to home-care
• Severe acute exacerbation of COPD: from ED to ICU

Areas covered will include:

• Cell to cell interactions/crosstalk in lung physiology and disease
• The lung: a dynamic interface with the environment
• Origins of diseases: from genetics to environmental effects
• Lung development and aging
• The latest from the lab: paving the way for therapeutic breakthroughs

Areas covered will include:

• How variability affects diagnosis and treatment outcomes in OSA in clinical practice and in clinical trials
• Central sleep apnoea – from pathophysiology over phenotypes to treatment recommendations
• Sex differences in sleep-disordered breathing
• Integrating evidence from different study designs to understand long-term outcomes in OSA and in CSA
• Personalised management of sleep-disordered breathing in obesity across the lifespan

Areas covered will include:

• Severe asthma; mucus plugs: from pathophysiology to diagnosis and clinical implications
• Combining biologics for airway diseases, asthma, and COPD
• Small molecules targeting airway diseases; moving therapeutics toward future
• Preventing the journey towards severe asthma
• Cough phenotyping: from the clinic to the treatment
• System biology in airway diseases; looking into big data to find answers for asthma and COPD

Areas covered will include:

• Lung trajectories and lifetime exposures and disease development across the globe.
• Environmental and occupational respiratory challenges: the view from the global south.
• Interventions in the face of occupational, environmental and lifestyle challenges.
• Tobacco and its environmental impact.
• Future city visions for better respiratory health.
• Prevention in respiratory health through smoking cessation and vaccinations.

Areas covered will include:

• Infections (asthma, PCD/bronchiectasis, CF): long term outcomes.
• Diversities of different diseases (prematurity and related respiratory disorders; asthma; respiratory infections).
• Global solutions to improve respiratory health: identification of risks (biomarkers/phenotypes); vaccination; disease observatories.
• Early roots of COPD: chronic lung disease of prematurity, impact of childhood disadvantage factors.
• Challenges in respiratory health worldwide: different priorities in different settings – smoking, air pollution, vaping.

Areas covered will include:

• Lung as a victim of humoral immunity
• Post-transplant viral infections
• Induction treatment in NSCLC
• Different surgical approaches to bilateral lung Tx
• AI and CT imaging in the evolution of solitary pulmonary nodules

Areas covered will include:

• Understanding and managing dyspnoea: a multidimensional perspective
• Exercise-training in severely impaired patients
• Supporting behaviour change in chronic respiratory disease
• Co-design and patient involvement in respiratory innovation
• Self-management of chronic respiratory diseases

Areas covered will include:

• Respiratory infections diagnostics
• Biomarkers in respiratory infections
• NTM – how long is enough when there is no response
• Antimicrobial resistance
• Global health in respiratory infections

Areas covered will include:

• 9th TNM edition for LC staging
• Early stage lung cancer, peri-operative management and ablative treatment alternatives
• Severe respiratory comorbidities affecting treatment decisions in early stages of LC
• Lung cancer screening update (eg. SOLACE/OPTIMA/IDERHA)
• The updated (9th Edition) of the TNM staging system for mesothelioma; practical implications

Areas covered will include:

• Infections in ILD – consequence or driver of fibrosis?
• Disappointments and new hopes for IPF & PPF therapies
• Pheno- and Endotypes in ILD
• ILA and screening for ILD
• Sarcoidosis 2025

Areas covered will include:

• Novel therapies in PAH
• PH and comorbidities
• Chronic thromboembolic disease
• Treatment decisions in acute pulmonary embolism patients at high risk
• Genetic phenotypes (icon groups)
• Radiology of pulmonary vascular disease

Areas covered will include:

• Lung nodules over the world: diagnosis, aetiology and treatment
• New invasive interventional procedures
• Management of complications of interventional procedures
• Diagnosis and treatment of pleural disease
• New developments in therapeutic bronchoscopy: COPD/chronic bronchitis